Actively Recruiting

All Genders
NCT06775561

Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-15

100

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

PARADIGM study, funded by the PNRR research grant, will focus on Eye Diseases (ED) and Neuro-Muscular Diseases (NMD) as groups of genetically heterogeneous diseases which are extensively studied by the Partners partecipating in the project; indeed ED and NMD are well clinically and molecularly characterized and approachable by drug-testing options already assessed and implemented by PARADIGM partners. ED and NMD represent good and compatible disease models as: * both are genetically heterogeneous disorders where missing heritability is likely to be hidden in non-coding variants; * many of the individual genes accountable for the ED and NMD cause autosomal recessive forms, increasing the chance of finding regulatory/splicing variants

CONDITIONS

Official Title

Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients or relatives of patients with a clinical diagnosis of neuromuscular diseases or eye diseases
  • Patients or relatives of patients with inconclusive exome sequencing (ES) and comparative genomic hybridization (aCGH) results, showing no pathogenic or likely pathogenic variant
  • Patients or relatives of patients with only one pathogenic or likely pathogenic variant found in an autosomal recessive gene by ES or aCGH
  • Patients or relatives of patients with detection of a large region of genomic homozygosity surrounding a candidate gene
  • Patients or relatives of patients with cryptic variants of uncertain significance (splicing, regulatory, noncoding CNVs) in eye or neuromuscular disease genes
  • Patients or relatives of patients with pathogenic cryptic variants in selected representative cases
  • Signed informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Families (trios or nuclear families) where both unaffected parents do not consent to participate
  • Multigenerational families with fewer than three affected family members

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy, 40138

Actively Recruiting

Loading map...

Research Team

T

Tommaso Pippucci, Biologist

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here